Highest-materiality recent filing
Atossa Q2 2026: OpEx $8.7M, R&D $4.9M; raises up to $16.5M from offering
Total operating expenses $8.7M in Q2 2026, down $0.3M from $9.0M in Q2 2025.
Atossa raises $4.5M in registered direct offering of stock and warrants
Sold 1,363,638 shares at $3.30/share plus Series A and B warrants for 1,363,638 shares each at $4.40.
Atossa shareholders approve reverse stock split up to 20:1, re-elect directors
Reverse stock split amendment approved: 2,336,815 for, 1,866,873 against, 33,271 abstentions.
Operating expenses $9.9M, up 34% YoY; FDA grants RPD for (Z)-endoxifen in DMD and McCune-Albright
Total operating expenses $9.9M in Q1 2026, up from $7.4M in Q1 2025, driven by higher legal fees for patent litigation (subsequently settled) and R&D costs.
Atossa settles patent disputes with Intas; Endoxifen patents remain enforceable
Entered Settlement Agreement on April 13, 2026 with Intas Pharmaceuticals and Jina Pharmaceuticals to resolve Endoxifen patent disputes.
Atossa Therapeutics Reports Q4 and FY2025 Results, Highlights (Z)-Endoxifen Progress in DMD
Atossa reported FY2025 operating expenses of $37.1M, up from $27.6M; R&D expenses increased 50% to $21.2M.
Atossa Therapeutics regains Nasdaq compliance on minimum bid price requirement
Received Nasdaq letter on Feb 17, 2026 confirming compliance with Listing Rule 5550(a)(2).
Atossa receives FDA Rare Pediatric and Orphan Drug designations for (Z)-endoxifen in DMD; pauses MBC
FDA Rare Pediatric Disease and Orphan Drug designations granted for (Z)-endoxifen in Duchenne Muscular Dystrophy (Dec 2025/Jan 2026).
FDA issued 'Study May Proceed' letter for Atossa's IND for (Z)-Endoxifen in metastatic ER+/HER2- breast cancer.
Atossa advances (Z)-endoxifen regulatory path; Q3 op-ex $9.3M
FDA Type C meeting set Nov 17 to discuss accelerated NDA path for (Z)-endoxifen in breast cancer risk reduction; written comments received.
Atossa appoints Mark Daniel as CFO to lead finance for commercial readiness
Mark Daniel appointed CFO effective Oct 14; Heather Rees transitions to non-officer employee through Nov 15.
Company requested a Type C FDA meeting; expects update by year-end 2025.
Atossa Therapeutics receives Nasdaq extension to Feb 17, 2026 for bid price compliance
Nasdaq notified Atossa on Feb 21, 2025 of non-compliance with $1.00 min bid price rule.
Atossa Q2 operating expenses $9M; FDA clears IND path for (Z)-endoxifen in metastatic breast cancer
Total operating expenses $9.0M in Q2 2025, up 27% YoY from $7.1M; R&D spend rose 55% to $5.5M.
Intas Pharmaceuticals challenges two Atossa endoxifen patents with PGR and IPR petitions at USPTO
Intas filed PGR petition against U.S. Patent No. 12,071,391, titled 'Methods for Making and Using Endoxifen'.
Atossa Therapeutics ends 2024 with $71.1M cash; advances (Z)-endoxifen for metastatic breast cancer
Cash and equivalents $71.1M, no debt; operating expenses fell to $27.6M from $31.4M in 2023.
Strategic decision to pursue metastatic breast cancer indication for (Z)-endoxifen, citing potentially faster regulatory path.
Atossa receives Nasdaq minimum bid price deficiency notice; compliance period through Aug 20, 2025
Received Nasdaq deficiency notice on Feb 21, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive business days.
PTAB invalidates Atossa's US Patent 11,572,334; new patent 12,201,591 issued
PTAB final decision found all claims of US Patent 11,572,334 unpatentable; Atossa will not appeal.
Atossa presents positive PK/tolerability data from Phase 2 EVANGELINE trial of (Z)-endoxifen
50% of patients on 80 mg (Z)-endoxifen + goserelin met target plasma Css of 500-1,000 ng/mL.
Atossa Therapeutics reports Q3 2024 results, highlights positive Phase 2 data for (Z)-endoxifen
Announced positive topline from KARISMA-Endoxifen Phase 2: MBD reductions of 19.3% (1 mg) and 26.5% (2 mg) vs placebo.
Atossa reports positive Phase 2 data for (Z)-endoxifen reducing breast density by up to 26.5%
Relative MBD reduction of 19.3% (1 mg) and 26.5% (2 mg) vs placebo in KARISMA-Endoxifen trial.
Atossa reports $79.5M cash, no debt; EVANGELINE Phase 2 40mg cohort shows 100% disease control rate
Ended Q2 2024 with $79.5M cash and cash equivalents, no debt; interest income $1.1M in Q2.
Atossa Q1 2024 net loss $5.9M; EVANGELINE 100% disease control at 24 weeks
Net loss of $5.9M (operating expenses $7.0M, interest income $1.1M); cash $84.0M, no debt.
Atossa reports FY2023 results: $88.5M cash, R&D spend up; two Phase 2 trials fully enrolled
Ended FY2023 with $88.5M cash and equivalents, no debt.
Atossa ends FY2023 with $88.5M cash; two Phase 2 studies fully enrolled, data due H2 2024
Cash and equivalents $88.5M as of Dec 31, 2023; no debt outstanding.
Atossa regains Nasdaq minimum bid price compliance; stock remains listed
Received Nasdaq letter on March 15, 2024 confirming regained compliance with Listing Rule 5550(a)(2).
Atossa receives Nasdaq deficiency notice for bid price below $1 for 30 days
Nasdaq letter dated September 26, 2023, citing non-compliance with Listing Rule 5550(a)(2) for minimum bid price.
Intas Pharmaceuticals files PGR petition challenging Atossa's endoxifen patent
Intas Pharmaceuticals filed a Post-Grant Review petition with USPTO challenging Atossa's U.S. Patent No. 11,572,334.
Atossa Therapeutics Q2 2023 net loss $9.8M; clinical enrollment milestones; CFO appointed
Cash at June 30, 2023: $99.4M, down from $110.9M at Dec 31, 2022.
Atossa Therapeutics regains Nasdaq compliance with minimum bid price requirement
Received Nasdaq notice on July 13, 2023 that it regained compliance with Listing Rule 5550(a)(2).
Atossa receives Nasdaq non-compliance notice for independent director majority rule
Received notice on June 21, 2023 for failing Nasdaq Listing Rule 5605(b)(1) requiring majority independent directors.
Atossa Q1 2023: cash $103.9M, no debt; Phase 2 trials initiated/expanded
Ended Q1 2023 with $103.9M cash and cash equivalents, zero debt.
On June 27, 2024, the Board of Directors (the “Board”) of the Company appointed Heather Rees, previously the Company’s Senior Vice President, Finance and Accounting, to serve as Chief Financial Officer and to continue serving as principal financial and accounting officer, effective immediately.
On March 9, 2024, the Board of Directors (the “Board”) of Atossa Therapeutics, Inc. (the “Company”) expanded its size and appointed Dr. Tessa Cigler, M.D., M.P.H. as a Class II director to hold office until the 2026 Annual Meeting of Stockholders and until her successor shall have been duly elected and qualified, effective immediately.
Jonathan Finn, CFA, has been appointed to the Company's board of directors, effective immediately.
Mr. Finn succeeded Greg Weaver as a Class I director
Mr. Weaver tendered his resignation to pursue other opportunities and not due to any disagreement with the Company.
In connection with Mr. Weaver’s resignation, the Company has appointed Heather Rees, age 51, as the Company’s principal financial and accounting officer.
Mr. Weaver’s termination of service as an employee served as his resignation from all other positions with the Company, including as a member of the Board of Directors.
Mr. Weaver succeeds Kyle Guse, who ceased to serve as the Company’s General Counsel and Chief Financial Officer as of May 26, 2023.
Effective as of June 1, 2023 (the “Effective Date”), Atossa Therapeutics, Inc. (the “Company”) appointed Greg Weaver as the Company’s Executive Vice President and Chief Financial Officer.
Max materiality 0.80 · Median 0.60 · Most common event other_material